Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study

Overview

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Description

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: neuroblastoma
  • Age: - 1 Years
  • Gender: Male or Female

Inclusion Criteria
12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Exclusion Criteria
Patients with MYCN amplified tumors


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022 . Study ID: TX4485

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center